• MJHLS Brand Logo

© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

A Closer Look at New FDA Guidance Removing Barriers to Biosimilar Development

October 30, 2025

FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability.

BioRationality: The FDA Sets Sights on Removing Clinical Efficacy Studies for Biosimilars

October 29, 2025

Biosimilars Improve Health System Resilience in Latin American, Caribbean Nations

October 28, 2025

Comparable Insulin Glargine Biosimilar Could Help Relieve Diabetes Costs

October 27, 2025

Data Confirm Biosimilar Ranibizumab Non-Inferiority as Myopic CNVM Treatment

October 24, 2025

Featured Content

Later-Line Therapies Drive Biosimilar Prescriptions in Turkish Rheumatology Practices

October 15th 2025

By Skylar Jeremias

Article

Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter disease duration, and female sex.

Biosimilar Bevacizumab Matches Avastin in Treating Retinopathy of Prematurity

October 14th 2025

By Skylar Jeremias

Article

A new study reveals Stivant, a bevacizumab biosimilar, matches Avastin in safety and efficacy for treating retinopathy of prematurity in infants.

FDA Approves Celltrion Aflibercept Biosimilar: Eydenzelt

October 13th 2025

By Skylar Jeremias

Article

The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.

Real-World Stability Confirmed for Biosimilar Ximluci in Prefilled Syringes

October 9th 2025

By Skylar Jeremias

Article

A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions.

Review Identifies Gaps in Evidence on Biosimilar DMARD Use During Pregnancy

October 9th 2025

By Skylar Jeremias

Article

A review of the safety of biosimilar DMARDs during pregnancy reveals critical evidence gaps and the need for informed clinical guidance.

Global Biosimilars Market Sees Gains in Access and Pipeline Expansion

October 7th 2025

By Skylar Jeremias

Article

The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market entries enhancing patient care.

Proposed Aflibercept Biosimilar Shows Comparable Safety, Efficacy in Phase 3 AMD Trial

October 2nd 2025

By Skylar Jeremias

Article

AVT06, a promising biosimilar to aflibercept (Eylea), shows comparable efficacy and safety for treating neovascular age-related macular degeneration (AMD), enhancing patient access.

Biosimilars News Roundup: September 2025

October 1st 2025

By Skylar Jeremias

Article

Biosimilar approvals surge in the US and Europe, enhancing access to denosumab and aflibercept therapies while driving significant health care savings.

Analysis Highlights Fiscal, Access Benefits of Omalizumab Biosimilars in Europe

September 30th 2025

By Skylar Jeremias

Article

Omalizumab biosimilars promise significant savings for European health systems, enhancing access to vital therapies for patients with severe allergies.

Biosimilar Tocilizumab Shows Cost-Effectiveness Advantage in Spanish RA Population

September 29th 2025

By Skylar Jeremias

Article

Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to advanced therapies.